uniQure N.V. logo

uniQure N.V.

NASDAQ:QURE

Overview | Financials
Company Name uniQure N.V.
Symbol QURE
Currency USD
Price 5.28
Market Cap 256,340,832
Dividend Yield 0%
52-week-range 4.25 - 20.412
Industry Biotechnology
Sector Healthcare
CEO Mr. Matthew Craig Kapusta
Website https://www.uniqure.com

An error occurred while fetching data.

About uniQure N.V.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a

Related Stocks

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

14.48 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

7.88 USD

Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

DSGN

3.77 USD

Erasca, Inc. logo

Erasca, Inc.

ERAS

2.22 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.532 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

22.73 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

11.53 USD

Financials

Numbers are in millions USD

Numbers are in millions USD